Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Inhibrx Biosciences to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.
Analyst Ratings
This is a summary of current recommendations and price targets for Inhibrx Biosciences and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
| Inhibrx Biosciences Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
Inhibrx Biosciences presently has a consensus target price of $185.00, indicating a potential upside of 168.23%. As a group, “Biotechnology” companies have a potential upside of 114.44%. Given Inhibrx Biosciences’ higher possible upside, equities research analysts plainly believe Inhibrx Biosciences is more favorable than its competitors.
Earnings & Valuation
This table compares Inhibrx Biosciences and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Inhibrx Biosciences | $1.30 million | -$140.05 million | -7.61 |
| Inhibrx Biosciences Competitors | $688.58 million | $7.69 million | -17.98 |
Inhibrx Biosciences’ competitors have higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Inhibrx Biosciences and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibrx Biosciences | N/A | -563.90% | -80.38% |
| Inhibrx Biosciences Competitors | -12,224.75% | -204.85% | -31.52% |
Volatility and Risk
Inhibrx Biosciences has a beta of 4.03, meaning that its share price is 303% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences’ competitors have a beta of -1.85, meaning that their average share price is 285% less volatile than the S&P 500.
Institutional and Insider Ownership
82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Inhibrx Biosciences beats its competitors on 7 of the 13 factors compared.
About Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
